TrialMultiple sclerosis and related disorders2020

Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis.

H-P Hartung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.